GRI Bio (NASDAQ: GRI) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
15 6월 2023 - 9:45PM
GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a
biotechnology company advancing an innovative pipeline of Natural
Killer T (“NKT”) cell modulators for the treatment of inflammatory,
fibrotic and autoimmune diseases, today announced that Marc Hertz,
Ph.D., Chief Executive Officer of GRI Bio, will present at the
Healthcare Virtual Conference Pat II, presented by Maxim Group LLC
and hosted by M-Vest on Thursday, June 22, 2023 at 12:00 PM ET.
The exponential growth in knowledge and
expertise in science and medicine continues to drive opportunities
in the healthcare space. These include multiple therapeutic
categories and emerging technologies, which presenting companies at
this year’s Maxim Healthcare Conference are focused on, and for
many, that includes key data-driven events in 2023. Maxim Senior
Analysts will host a wide range of biotechnology and medical device
companies in a series of presentations and interactive discussions
with CEOs and key management. Maxim will also be hosting several
topical industry panels that promise to be timely and engaging.
This conference will be live on M-Vest. To
attend, just sign up to become an M-Vest member.
Click Here to Reserve Your Seat. About
GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical
company focused on fundamentally changing the way inflammatory,
fibrotic and autoimmune diseases are treated. GRI Bio’s therapies
are designed to target the activity of NKT cells, which are key
regulators earlier in the inflammatory cascade, to interrupt
disease progression and restore the immune system to homeostasis.
NKT cells are innate-like T cells that share properties of both NK
and T cells and are a functional link between the innate and
adaptive immune responses. Type I invariant NKT (“iNKT”) cells play
a critical role in propagating the injury, inflammatory response,
and fibrosis observed in inflammatory and fibrotic indications. GRI
Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity
and is being developed as a novel oral therapeutic for the
treatment of idiopathic pulmonary fibrosis, a serious disease with
significant unmet need. The Company is also developing a pipeline
of novel type 2 NKT agonists for the treatment of systemic lupus
erythematosus. Additionally, with a library of over 500 proprietary
compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:JTC Team,
LLCJenene Thomas(833) 475-8247GRI@jtcir.com
GRI Bio (NASDAQ:GRI)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
GRI Bio (NASDAQ:GRI)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024